Hvis en bivirkning forekom med større frekvens i det integrerede fase III- forsøg (Intrinsa- patienter n=1. 498, placebo- patienter n=1. 297), vil denne frekvens være rapporteret i tabellen.
If an adverse reaction occurred at a higher frequency in the integrated phase III studies (Intrinsa patients n=1,498, placebo patients n=1,297), this frequency is reported in the table.